Back to search
FDAFDA · Food and drugs·Recall number D-0331-2022

basic+care, allergy Fexofenadine Hydrochloride Tablets, 180 mg/Antihistamine, 24 HR, 150 count bottle, Made in the Czech Republic, Distributed by: Perrigo Allergan, MI 49010, NDC 0113-7571-47 UPC 3 70030 11470 2

Published January 12, 2022 · Recall initiated: July 27, 2021

Summary

FDA records drug Class II recall D-0331-2022, published January 12, 2022 and initiated July 27, 2021. Recalling firm: Perrigo Company PLC; Status: Terminated; Reported quantity: 28,320 containers; Lot: Lot # 0GR0528, Exp 03/31/22; 0KR0473, Exp 04/30/22; 0LR0369, Exp 06/30/22. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Perrigo Company PLC
Distributor
Nationwide in the USA
Lot
Lot # 0GR0528, Exp 03/31/22; 0KR0473, Exp 04/30/22; 0LR0369, Exp 06/30/22
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was basic+care, allergy Fexofenadine Hydrochloride Tablets, 180 mg/Antihistamine, 24 HR, 150 count bottle, Made in the Czech Republic, Distributed by: Perrigo Allergan, MI 49010, NDC 0113-7571-47 UPC 3 70030 11470 2 recalled?

Yes. FDA published recall D-0331-2022 on January 12, 2022. Reported hazard: Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter